畔上　達彦 （アゼガミ　タツヒコ）

Azegami, Tatsuhiko

写真a

所属（所属キャンパス）

医学部 内科学教室（腎臓・内分泌・代謝） （信濃町）

職名

専任講師

外部リンク
このページの先頭へ▲

その他の所属・職名 【 表示 ／ 非表示 】

  • 医学部, 腎臓・内分泌・代謝内科

このページの先頭へ▲

経歴 【 表示 ／ 非表示 】

  • 2010年04月
    -
    2012年03月

    慶應義塾大学大学院, 医学研究科, 研究奨励助教

  • 2012年04月
    -
    2013年03月

    慶應義塾大学　医学部, MSD抗加齢内分泌学寄付講座, 特任助教

  • 2013年04月
    -
    2017年03月

    慶應義塾大学　医学部, 内科学（腎臓内分泌代謝）, 助教

  • 2017年04月
    -
    2019年03月

    東京大学医科学研究所, 感染・免疫部門　炎症免疫学分野, 客員研究員

  • 2017年04月
    -
    2021年03月

    慶應義塾大学, 保健管理センター, 助教

全件表示 >>

このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 2001年04月
    -
    2007年03月

    慶応義塾大学, 医学部

    大学, 卒業

  • 2009年04月
    -
    2012年03月

    慶応義塾大学, 医学研究科, 内科学

    大学院, 卒業, 博士

このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 医学博士, 慶應義塾大学大学院, 課程, 2012年03月

このページの先頭へ▲

免許・資格 【 表示 ／ 非表示 】

  • 日本内科学会　認定医, 2010年

  • 日本内科学会　総合内科専門医, 2013年

  • 日本透析医学会　専門医, 2013年

  • 日本腎臓学会　腎臓専門医, 2013年

  • 日本高血圧学会　高血圧専門医, 2014年

全件表示 >>

このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス / 腎臓内科学

このページの先頭へ▲

研究キーワード 【 表示 ／ 非表示 】

  • ワクチン

  • 生活習慣病

  • 粘膜免疫

  • 腎病理

  • 高血圧

このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • Immunotherapy for obesity

    Azegami T., Itoh H., Therapeutic Vaccines as Novel Immunotherapy: Biological and Clinical Concepts, 2020年01月

    　概要を見る

    Obesity prevalence continues to increase in both adults and children worldwide and greatly contributes to increased morbidity and mortality. Although there are some anti-obesity drugs globally available for clinical use, their inadequate effectiveness coupled with safety concerns sometimes discourage the widespread use of anti-obesity medication. Because of its prolonged therapeutic effect and low frequency of administration, a therapeutic vaccine may be an attractive strategy for the prevention and treatment of obesity. Over the last two decades, several attempts have been made to develop vaccines for the control of obesity. Animal studies have shown that vaccines targeting ghrelin, glucose-dependent insulinotropic polypeptide, adipocytes, somatostatin, and adenovirus 36 successfully led to a reduction in weight gain without serious adverse effects. This chapter provides an overview of recent progress toward a therapeutic vaccine against obesity.

  • Mucosal Vaccines: Innovation for Preventing Infectious Diseases, 2nd edition.

    Elsevier, 2020年

    担当範囲: Plant-Based Mucosal Vaccine Delivery System,  担当ページ： 357-370

  • Plant-based mucosal vaccine delivery systems

    Azegami T., Yuki Y., Kiyono H., Mucosal Vaccines: Innovation for Preventing Infectious Diseases, 2019年01月

    　概要を見る

    Plant-based vaccines (PbVs), developed with novel plant genetic engineering technologies, offer a new strategy for the production, storage, and delivery of vaccines. PbVs can overcome practical and economic concerns surrounding injectable vaccines, including the need for medical staff to perform the injections and the costs of production and refrigeration. The development of unrefrigerated, needle-free vaccines will support the prevention of infectious diseases in developing countries. Although no PbV has yet been licensed for human clinical use, some are now in clinical trials. Antigen-encoding genes introduced into potatoes, lettuce, spinach, corn, tobacco, soybeans, and rice can produce vaccines against mucosal and systemic infectious diseases, including enterotoxigenic Escherichia coli, Vibrio cholerae, norovirus, influenza virus, hepatitis B virus, and rabies virus. This chapter introduces the plant genetic engineering technologies used and clinical trials of PbVs.

  • Therapeutic Vaccines as Novel Immunotherapy

    Springer, 2019年

    担当範囲: Immunotherapy for Obeisty,  担当ページ： 33-44

  • 腎生検病理アトラス改訂版（尿細管・間質・血管病変の分類）

    畔上達彦、山口裕, 2017年08月

全件表示 >>

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Vaccination against connective tissue growth factor attenuates the development of renal fibrosis

    Nakayama T., Azegami T., Hayashi K., Hishikawa A., Yoshimoto N., Nakamichi R., Sugita E., Itoh H.

    Scientific Reports （Scientific Reports）  12 （ 1 ） 10933 2022年12月

    ISSN  2045-2322

    　概要を見る

    There is a critical need for efficient treatment of chronic kidney disease (CKD). Renal fibrosis is a final common pathway to end-stage renal disease independent of the underlying etiology, and connective tissue growth factor (CTGF) is a well-recognized profibrotic factor in fibrosis of various organ systems. Here, we developed a novel peptide vaccine against CTGF to attenuate the development of renal fibrosis. Three inoculations with this CTGF vaccine at 2-week intervals elicited antibodies specifically binding to human full-length CTGF, and the antigen-specific serum IgG antibody titers were maintained for > 30 weeks. The efficacy of the CTGF vaccine on renal fibrosis was evaluated in adenine-induced CKD and unilateral ureteral obstruction (UUO) murine models. In adenine-induced CKD model, immunization with the CTGF vaccine attenuated renal interstitial fibrosis. Vaccinated mice showed low levels of serum creatinine and urea nitrogen and low urine albumin–creatinine ratio compared with vehicle-treated mice. In UUO model, the CTGF vaccination also suppressed the onset of renal fibrosis. In an in vitro study, CTGF vaccine-elicited IgG antibodies efficiently suppressed CTGF-induced- and transforming growth factor-β-induced α-smooth muscle actin expression in kidney fibroblasts. These results demonstrate that the CTGF vaccine is a promising strategy to attenuate the development of renal fibrosis.

  • Serum thymus and activation-regulated chemokine level is associated with the severity of chronic kidney disease-associated pruritus in patients undergoing peritoneal dialysis

    Nakayama T., Morimoto K., Uchiyama K., Kusahana E., Washida N., Azegami T., Kanda T., Yoshida T., Itoh H.

    Peritoneal Dialysis International （Peritoneal Dialysis International）  42 （ 4 ） 415 - 424 2022年07月

    ISSN  08968608

    　概要を見る

    Background: Thymus and activation-regulated chemokine (TARC), which induces a Th2-dominated inflammation, is a well-known biomarker that reflects the severity of atopic dermatitis. The present study aimed to evaluate TARC as a Th2-associated marker with chronic kidney disease-associated pruritus (CKD-aP) in patients with peritoneal dialysis (PD). Methods: This single-centre cross-sectional study included patients who underwent PD in our hospital between August 2020 and July 2021. The severity and impaired quality of life (QOL) of CKD-aP were assessed using the visual analogue scale (VAS) and Japanese version of the 5-D itch scale (5D-J), respectively. Results: A total of 48 patients with PD were included in the present study. Age and dialysis vintage were (mean ± SD) 64.8 ± 12.0 year and (median (IQR)) 38.5 (11.5–91.5) month, respectively. VAS and 5D-J scores were 3.3 ± 2.0 and 10.5 (9.0–12.0), respectively. Serum TARC level was 481.5 (278.9–603.4) pg/mL (upper limits of normal 450 pg/mL) and significantly correlated with VAS (r = 0.39, p = 0.006) and 5D-J score (r = 0.37, p = 0.009). Multivariate linear analysis revealed that higher serum TARC level was significantly associated with VAS (p < 0.001) and 5D-J score (p < 0.001). Furthermore, the serum brain natriuretic peptide level tended to be associated with VAS (p = 0.060) and 5D-J score (p = 0.029). Conclusion: Serum TARC level is an independent predictor of the severity and impaired QOL of CKD-aP in patients with PD, and TARC might be involved in the pathogenesis of CKD-aP.

  • Late Dialysis Modality Education Could Negatively Predict Peritoneal Dialysis Selection

    Nakayama Takashin, Nishioka Ken, Uchiyama Kiyotaka, Morimoto Kohkichi, Kusahana Ei, Washida Naoki, Yamaguchi Shintaro, Azegami Tatsuhiko, Yoshida Tadashi, Itoh Hiroshi

    JOURNAL OF CLINICAL MEDICINE 11 （ 14 ）  2022年07月

  • Effects of renin-angiotensin system inhibitors on the incidence of unplanned dialysis

    Nakayama T., Morimoto K., Uchiyama K., Kusahana E., Washida N., Azegami T., Kanda T., Yoshida T., Itoh H.

    Hypertension Research （Hypertension Research）  45 （ 6 ） 1018 - 1027 2022年06月

    ISSN  09169636

    　概要を見る

    Unplanned dialysis initiation is associated with poor outcomes. It is controversial whether patients with advanced chronic kidney disease (CKD) should receive renin-angiotensin system (RAS) inhibitor therapy. The aim of this study was to evaluate the effect of RAS inhibitor therapy in patients with advanced CKD on the incidence of unplanned dialysis initiation. This single-center, retrospective study included patients who started maintenance dialysis at our hospital between April 2014 and March 2021. Patients who initiated dialysis within 6 months of nephrology referral or after kidney transplant were excluded. Among 334 patients (aged 70.0 [59.0–79.0] years; 28.4% women), 186 (55.7%) and 148 (44.3%) had planned and unplanned dialysis initiation, respectively. Multivariate logistic regression analysis revealed that the use of RAS inhibitors was significantly associated with a lower incidence of unplanned dialysis initiation (odds ratio [OR], 0.36; P < 0.01). Female sex (OR, 0.41; P < 0.05), use of potassium binders (OR, 0.28; P < 0.001), earlier referral to nephrology (OR, 0.39; P < 0.01), and earlier discussion of renal replacement therapy (OR, 0.33; P < 0.001) were also significantly associated with a lower incidence, whereas older age (OR, 1.28; P < 0.05), higher Charlson Comorbidity Index (OR, 1.24; P < 0.05), and faster decline in kidney function (OR, 1.29; P < 0.01) were associated with a higher risk of unplanned dialysis initiation. RAS inhibitor therapy in patients with advanced CKD is associated with a lower risk of unplanned dialysis initiation.

  • Fibronectin Glomerulopathy Confused with Glomerular Endothelial Injury in a Patient with Takotsubo Cardiomyopathy

    Azegami T., Hashiguchi A., Nakayama T., Hayashi K., Kanda T., Itoh H.

    Internal Medicine （Internal Medicine）  61 （ 13 ） 2027 - 2032 2022年

    ISSN  09182918

    　概要を見る

    A 46-year-old woman developed takotsubo cardiomyopathy and nephrotic syndrome. The first kidney biopsy suggested non-immune-complex-mediated membranoproliferative glomerulonephritis (MPGN), and she was diagnosed with glomerular endothelial injury associated with takotsubo cardiomyopathy. A second biopsy was performed two years later because of persistent proteinuria despite renin-angiotensin system inhibition. This biopsy indicated non-immune-complex-mediated MPGN, but a mesangial and subendothelial substance of a higher electron density than that in the first biopsy was detected, suggesting the possibility of glomerular disease with non-immune deposits rather than endothelial injury. Finally, she was diagnosed with fibronectin nephropathy. Although rare, fibronectin glomerulopathy should be considered in non-immune-complex-mediated MPGN.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 慢性腎臓病に対する新規治療戦略の開発研究

    2021年04月
    -
    2024年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 畔上 達彦, 基盤研究(C), 補助金,  研究代表者

  • 糖尿病性腎症に対する新規治療戦略の開発

    2018年04月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 畔上　達彦, 若手研究, 補助金,  研究代表者

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • 第9回臨床高血圧フォーラム　Young Clinician Award 最優秀賞

    2021年05月

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • Asian-Pacific Society of Hypertension Young Investigator Fellowships

    2018年10月

    受賞区分： 国際学会・会議・シンポジウム等の賞

  • 第8回臨床医学研究塾 奨励賞

    2017年10月, 第8回臨床医学研究塾

  • Premium Hypertension Conference 優秀演題賞

    2015年08月, Premium Hypertension Conference

  • Asian-Pacific Society of Hypertension Young Investigator Fellowships

    2012年10月, International Society of Hypertension

全件表示 >>

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 慢性期病態学各論

    2024年度

  • 現代社会と医学Ⅰ

    2023年度

  • 現代社会と医学Ⅰ

    2022年度

  • 現代社会と医学Ⅰ

    2021年度

  • 現代社会と医学Ⅱ

    2020年度

全件表示 >>

このページの先頭へ▲
 

所属学協会 【 表示 ／ 非表示 】

  • 日本内科学会

    　

  • 日本腎臓学会

    　

  • 日本高血圧学会

    　

  • 日本透析医学会

    　

  • 日本腎病理協会

    　

全件表示 >>

このページの先頭へ▲